Table 1

Baseline characteristics of the 21 study patients

No. (%)
 CharacteristicOverall (n=21)Cohort 1:
SBRT 8GyX5+nivolumab
(HPV+)
Cohort 2:
SBRT 8GyX3 +
Nivolumab
(HPV+)
Cohort 3:
SBRT 8GyX3
(HPV+)
Cohort 4:
SBRT 8GyX3+nivolumab
(HPV−)
Age, median (range), years62.8 (50.1–76.0)60.6 (50.1–75.5)68.4 (61.0–76.4)60.5 (53.1–66.4)62.2 (50.1–69.4)
 Sex
 Male19 (90.5)5 (100)5 (100)5 (83.3)4 (80.0)
 Female2 (9.5)001 (16.7)1 (20.0)
Smoker
 No11 (52.4)4 (80.0)1 (20.0)5 (83.3)1 (20.0)
 Former, ≤10 packs year3 (14.3)1 (20.0)1 (20.0)1 (16.7)0
 Former, ≥10 packs year7 (33.3)03 (60.0)04 (80.0)
Primary tumor site
 Oropharynx15 (71.4)4 (80.0)4 (80.0)6 (100)1 (20.0)
 Oral cavity2 (9.5)0002 (40.0)
 Larynx2 (9.5)0002 (40.0)
 Unknown primary2 (9.5)1 (20.0)1 (20.0)00
Pretreatment clinical T-stage
 X1 (4.8)1 (20.0)000
 02 (9.5)1 (20.0)1 (20.0)00
 14 (19.0)01 (20.0)2 (33.3)1 (20.0)
 29 (42.9)3 (60.0)3 (60.0)3 (50.0)0
 31 (4.8)001 (16.7)0
 4A4 (19.0)0004 (80.0)
Pretreatment clinical N-stage
 N02 (9.5)001 (16.7)1 (20.0)
 N116 (76.2)5 (100.0)5 (100.0)5 (83.3)1 (20.0)
 N2c2 (9.5)0002 (40.0)
 N31 (4.8)0001 (20.0)
AJCC overall clinical stage (AJCC, 8th Edition)
 I15 (71.4)5 (100.0)5 (100.0)5 (83.3)0
 II1 (4.8)001 (16.7)0
 III00000
 IVA4 (19.0)0004 (80.0)
 IVB1 (4.8)0001 (20.0)
  • HPV, human papilloma virus; SBRT, stereotactic body radiation therapy.